2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
T

2020 ASCO Updates on IDH2-Mutated ND-AML: ENA+AZA vs. AZA Mono - What Are the OS/Remission Effects? Is This Combination Clinically Meaningful?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Terrence Bradley
By 2020 ASCO Virtual Direct™ Highlights FEATURING Terrence Bradley
100 views
September 29, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

20:09
AstraZeneca Oncology

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam
Hematologic Oncology
07:56
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on IDH1-Mutated AML: Do Ivosidenib & Venetocla…

Feat. T. Bradley
07:27
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on IDH2-Mutated ND-AML: ENA+AZA vs. AZA Mono - Wha…

Feat. T. Bradley
09:26
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on R/R AML: Is AMG 330 Safe and Tolerable? How …

Feat. T. Bradley
11:17
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on MDS/AML: How Does Magrolimab Work With AZA? Wha…

Feat. T. Bradley
09:41
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on R/R Hodgkin Lymphoma: Can We Consider Pembrolizu…

Feat. W. Hammond
07:33
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Waldenstrom Macroglobulinemia: Clinical Benefit …

Feat. W. Hammond
07:51
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Lymphomas: Is Axi-Cel Effective in R/R Indolent …

Feat. W. Hammond
07:03
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on CLL: Does Venetoclax + da-EPOCH-R Show Promise f…

Feat. W. Hammond